<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01655888</url>
  </required_header>
  <id_info>
    <org_study_id>MESOT-TREM-2012</org_study_id>
    <secondary_id>2012-002762-12</secondary_id>
    <nct_id>NCT01655888</nct_id>
  </id_info>
  <brief_title>The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma</brief_title>
  <official_title>A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Senese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Senese</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of&#xD;
      tremelimumab in malignant mesothelioma (MM) patients.&#xD;
&#xD;
      PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive&#xD;
      schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive&#xD;
      investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until&#xD;
      confirmed disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:&#xD;
&#xD;
      1) To assess the rate of objective clinical complete response (CR) or partial response (PR)&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        1. To define toxicity profile according to NCI CT-CAE V. 3&#xD;
&#xD;
        2. To assess the overall survival (OS)&#xD;
&#xD;
        3. To estimate disease control rate (DCR) (proportion of patients with best response of&#xD;
           CR+PR+SD) according to the modified Recist criteria&#xD;
&#xD;
        4. To assess the progression-free survival in treated patients according to modified Recist&#xD;
           criteria&#xD;
&#xD;
        5. To evaluate qualitative and quantitative changes in cellular and humoral immune&#xD;
           responses&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the objective response</measure>
    <time_frame>Weeks 24</time_frame>
    <description>The objective response is defined as a confirmed complete response (CR), or partial response (PR) according to the modified RECIST Criteria for pleural mesothelioma and the immune-related (ir) Response Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
    <description>DCR is the proportion of treated subjects that achieved confirmed CR or PR or stable disease (SD) The DCR is assessed using the modified RECIST Criteria for pleural mesothelioma umor assessment and the the immune-related response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 years</time_frame>
    <description>The assessment of safety includes serious and non-serious adverse events according to NCI-CTC criteria version 3.0. In addition, laboratory evaluation, abnormal vital signs and physycal examination findings are also included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 years</time_frame>
    <description>Progression free survival is computed from the first day of study treatment to the day of documented progression according to the modified RECIST Criteria for pleural mesothelioma or death, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <arm_group>
    <arm_group_label>single arm with Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Tremelimumab is administered as endovenous infusion</description>
    <arm_group_label>single arm with Tremelimumab</arm_group_label>
    <other_name>CP-675,206</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed MM&#xD;
&#xD;
          -  Have received only one prior systemic chemotherapy platinum-based regimen for advanced&#xD;
             MM&#xD;
&#xD;
          -  Measurable disease, defined at least 1 unidimensionally measurable lesion &gt; 20 mm by&#xD;
             conventional techniques or &gt; 10 mm by spiral CT scan (modified RECIST criteria)&#xD;
&#xD;
          -  Disease not amenable to curative surgery&#xD;
&#xD;
          -  No known brain metastasis&#xD;
&#xD;
          -  Age 18 and over&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Adequate hematologic, hepatic and renal function&#xD;
&#xD;
          -  Platelet count &gt; 75000/mm3&#xD;
&#xD;
          -  Absolute granulocyte count &gt; 1000/mm3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Bilirubin total &lt; 1.5 x ULN (Upper limited normal), except patients with documented&#xD;
             Gilbert's syndrome, who must have a total bilirubin &lt; 3.0 mg/dl&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 x ULN ( &lt; 5 x ULN if documented liver metastasis are present)&#xD;
&#xD;
          -  Creatinine level &lt; 2mg/dl or calculated creatinine clearance &gt; 60 mL/min as determined&#xD;
             by the Cockcroft Gault equation.&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Patient must be willing and able to provide written informed consent, and the trial&#xD;
             have to be approved by the institutional review board at each institution&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic chronic inflammatory or autoimmune disease&#xD;
&#xD;
          -  Active hepatitis B or C&#xD;
&#xD;
          -  Prior treatment with tremelimumab or other anti-CTLA-4 antibody or anti-PD1,&#xD;
             anti-PDL-1 agents&#xD;
&#xD;
          -  Clinically relevant cardiovascular disease&#xD;
&#xD;
          -  History of psychiatric disabilities, potentially interfering with the capability of&#xD;
             giving adequate informed consent&#xD;
&#xD;
          -  Uncontrolled active infections&#xD;
&#xD;
          -  Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational agents&#xD;
&#xD;
          -  History of other malignancies except for adequately treated basal cell carcinoma or&#xD;
             squamous cell skin cancer or carcinoma of cervix, unless the patient has been&#xD;
             disease-free for at least 5 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Maio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luana Calabrò, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology and Immunotherapy, University Hospital of Siena, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Maio, MD</last_name>
    <phone>+39-0577586335</phone>
    <email>mmaio@cro.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luana Calabrò, MD</last_name>
    <phone>+39-0577586116</phone>
    <email>l.calabro@ao-siena.toscana.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Oncology and Immunotherapy Unit, University Hospital of Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Maio, MD</last_name>
      <phone>+39-0577586335</phone>
      <email>mmaio@cro.it</email>
    </contact>
    <contact_backup>
      <last_name>Luana Calabrò, MD</last_name>
      <phone>+39-0577586116</phone>
      <email>l.calabro@ao-siena.toscana.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Maio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luana Calabrò, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 31, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2012</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Senese</investigator_affiliation>
    <investigator_full_name>Michele Maio</investigator_full_name>
    <investigator_title>Head of Medical Oncology and Immunotherapy Unit</investigator_title>
  </responsible_party>
  <keyword>Tremelimumab</keyword>
  <keyword>anti-CTLA-4 monoclonal antibody</keyword>
  <keyword>malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

